IRulya Therapeutics (IRLA) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Valneva is the larger company by market cap ($490.9 million vs $432.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRLA | VALN |
|---|---|---|
| Share price | $39.88 | $5.16 |
| Market cap | $432.36M | $490.86M |
| 1-day change | -0.15% | -3.82% |
| YTD return | — | -41.50% |
| 1-year return | — | -40.14% |
| 5-year return | — | -91.34% |
| Forward P/E | — | 4.34 |
| EPS (TTM) | $-162.79 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-83.98M | — |
| 52-week high | $910.00 | $12.18 |
| 52-week low | $15.10 | $4.75 |
| Distance from 52-week high | -95.62% | -57.64% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +90.90% | +137.98% |
| Average volume | 63.03K | 23.10K |
| Shares outstanding | 10.84M | 95.13M |
| Employees | 38 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About IRulya Therapeutics
IRLA stock →IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
IRLA vs VALN FAQ
Which is bigger, IRulya Therapeutics or Valneva?
Valneva (VALN) is larger, with a market capitalization of $490.86M compared with $432.36M for IRulya Therapeutics (IRLA).
Are IRulya Therapeutics and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.